Bartholin gland carcinoma

Summary

Bartholin gland carcinoma (MONDO:0002829) is a cancer. A subtype of integumentary system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bartholin gland carcinoma
Mondo ID	MONDO:0002829
EFO	EFO:1000103
DOID	DOID:3999, DOID:60003
NCIT	C9055
SNOMED CT	276876007
UMLS	C0349561
MedGen	83888
GARD	0023257
Anatomy (UBERON)	UBERON:0000460
Is cancer (heuristic)	yes

Also known as: Bartholin gland cancer · bartholin gland carcinoma · Bartholin gland carcinoma (disease) · Bartholin’s gland cancer · Bartholin’s gland carcinoma · carcinoma of Bartholin’s gland · carcinoma of major vestibular gland · carcinoma of the Bartholin’s gland · major vestibular gland carcinoma

Data availability: 1 HPO phenotype.

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › bartholin gland carcinoma

Related subtypes (6): skin cancer, nipple carcinoma, breast adenocarcinoma, atypical lobular breast hyperplasia, breast diffuse large B-cell lymphoma, dermatofibrosarcoma protuberans

Subtypes (4): Bartholin gland transitional cell carcinoma, Bartholin gland adenocarcinoma, bartholin gland squamous cell carcinoma, Bartholin gland small cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.